Computed tomography-based radiomics predicts the fibroblast-related gene EZH2 expression level and survival of hepatocellular carcinoma

Table 2 Relationship between risk score and clinicopathological parameters in hepatocellular carcinoma patients

Variables	Total, n = 339	Risk score-low, n = 170	Risk score-high, n = 169	P value
Age	61.000 (51.000, 68.000)	62.000 (52.000, 69.000)	59.000 (51.000, 67.000)	0.083
Sex				0.310
Female	107 (31.6%)	58 (34.1%)	49 (29.0%)
Male	232 (68.4%)	112 (65.9%)	112 (71.0%)
Stage				0.876
S1+S2	252 (74.3%)	127 (74.7%)	125 (74.0%)
S3+S4	87 (25.7%)	43 (25.3%)	44 (26.0%)
Grade				0.457
G1+G2	212 (62.5%)	103 (60.6%)	109 (64.5%)
G3+G4	127 (35.5%)	67 (39.4%)	60 (35.5%)

S1 + S2: Stage I and stage II; S3 + S4: Stage III and stage IV.